Structural and microvascular alterations in clinically unaffected fellow eyes of patients with acute central serous chorioretinopathy: An OCT and OCTA study
Northern Clinics of Istanbul · 20.07.2026 · 274-279
DOI: 10.14744/nci.2026.43403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Northern Clinics of Istanbul, erschienen am 20.07.2026. Verfasst von Guzide Akcay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye.
- Department of Advanced Neurological Sciences, Istanbul University Institute of Graduate Studies in Health Sciences, Istanbul, Turkiye.
- Department of Administration, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye.
Zitieren
APA
Akcay, G., Kivrak, U., Yaprak, D. C., Bogazliyan, O. F., & Buyukmurat, N. (2026). Structural and microvascular alterations in clinically unaffected fellow eyes of patients with acute central serous chorioretinopathy: An OCT and OCTA study. Northern Clinics of Istanbul, 274-279. https://doi.org/10.14744/nci.2026.43403
Vancouver
Akcay G, Kivrak U, Yaprak DC, Bogazliyan OF, Buyukmurat N. Structural and microvascular alterations in clinically unaffected fellow eyes of patients with acute central serous chorioretinopathy: An OCT and OCTA study. Northern Clinics of Istanbul. 2026:274-279. doi:10.14744/nci.2026.43403
BibTeX
@article{Akcay2026,
author = {Akcay, Guzide and Kivrak, Ulviye and Yaprak, Dilber Celik and Bogazliyan, Omer Faruk and Buyukmurat, Neslihan},
title = {Structural and microvascular alterations in clinically unaffected fellow eyes of patients with acute central serous chorioretinopathy: An OCT and OCTA study},
journal = {Northern Clinics of Istanbul},
year = {2026},
pages = {274--279},
doi = {10.14744/nci.2026.43403}
}
EUVIMED